MedTrace Logo

Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure

NCT02864316 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-08-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Nivolumab is effective in the treatment of radiation-induced solid tumors.

Conditions

  • Solid Tumors Induced by Prior Radiation Exposure

Interventions

DRUG

Nivolumab

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Patrick Forde, MB, BCH · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-08-31
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02864316 on ClinicalTrials.gov